ERVW-1 and infection: Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope protein (Env) can prevent infection in animal models and are under investigation for passive immunization in clinical trials (Balazs et al., 2011, Gautam et al., 2016, Julg and Barouch, 2019, Moldt et al., 2012, Shingai et al., 2014).